Pingming Gao

Pingming Gao


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2021 in Food & Function
Verified
Journal Article
Closed access
PDF file
ZTZhuohong Tang
Zhuohong Tang
TLTing Luo
Ting Luo
PHPeng Huang
Peng Huang
MLMi Luo
Mi Luo
JZJianghua Zhu
Jianghua Zhu
Shuwen LiuShuwen Liu
Shuwen Liu
Gestational diabetes mellitus (GDM) has become a global health concern as the main result of its contribution to the high risk of adverse pregnancy outcomes for both the mother and fetus. However, there is absence of an ideal and widely acceptable therapy. Nuciferine has previously been shown to exert beneficial effects in various metabolic diseases. This study aimed to investigate the potential therapeutic efficacy of nuciferine on GDM in C57BL/6J mice induced by a high-fat diet (HFD), which has not been reported before. The results showed that nuciferine improved glucose intolerance, reduced lipid accumulation and increased the glycogen content within hepatocytes, and decreased placental lipid and glycogen deposition, thus ameliorating glycolipid disorders in GDM mice. Additionally, nuciferine protected against histological degeneration of metabolism-associated critical organs including the liver, pancreas, and abdominal adipose tissue. Most interestingly, nuciferine could correct intestinal dysbacteriosis in GDM mice, as evidenced by the elevation of probiotic abundances consisting of Akkermansia, Lactobacillus, and Bifidobacterium, which were all negatively correlated with serum and liver triglyceride (TG) and positively associated with hepatic glycogen, and the reduction of conditional pathogen abundances including Escherichia–Shigella and Staphylococcus, and the latter was positively related to serum and liver TG and negatively linked with liver glycogen. Collectively, these findings suggest that nuciferine as a food-borne strategy played important roles in the management of GDM.

1 January 2021 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
MLMi Luo
Mi Luo
LZLiyun Zheng
Liyun Zheng
SWSuwei Wang
Suwei Wang
JZJianghua Zhu
Jianghua Zhu
ZTZhuohong Tang
Zhuohong Tang
PGPingming Gao
Pingming Gao

9 August 2018 in Pediatrics & Neonatology
Verified
Journal Article
Open access
PDF file
XGXiaoyan Gao
Xiaoyan Gao
FMFei Ma
Fei Ma
HHHu Hao
Hu Hao
YDYiheng Dai
Yiheng Dai
WLWeidong Liu
Weidong Liu
SLSitao Li
Sitao Li
Background To examine whether polymorphisms in the VEGFA gene lead to low VEGFA production in peripheral blood and increased risk of NEC in the Chinese Han population. Material and methods Thirty NEC patients and 80 control subjects were enrolled. Six VEGFA single-nucleotide polymorphisms (SNPs) were performed using the SEQUENOM MassARRAY platform assay. The concentration of VEGFA in the plasma was measured using an enzyme-linked immunosorbent assay. Results The rs699947 and rs833061 VEGF-A SNPs were found to be associated with low plasma levels and high risk of NEC. Conclusion Our results suggested that, if validated in larger studies, screening for VEGFA SNPs and plasma levels might be useful as a risk factor for NEC in the future.

4 March 2019 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
ZLZhigang Liu
Zhigang Liu
XYXingguang Ye
Xingguang Ye
PQPeixiu Qiao
Peixiu Qiao
WLWeiyao Luo
Weiyao Luo
YWYanling Wu
Yanling Wu
PGPingming Gao
Pingming Gao

11 January 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
YZYueqin Zhou
Yueqin Zhou
XCXiaoyan Chen
Xiaoyan Chen
TLTianze Li
Tianze Li
PGPingming Gao
Pingming Gao
SHSaijun Huang
Saijun Huang
YZYanna Zhu
Yanna Zhu
Background/Objectives: We aimed to identify neonatal circulating metabolic alterations associated with maternal gestational diabetes mellitus (GDM) and to explore whether these altered metabolites could mediate the association of GDM with offspring neurodevelopment. Additionally, we investigated whether neonatal circulating metabolites could improve the prediction of offspring neurodevelopmental disorders over traditional risk factors. Methods: The retrospective cohort study enrolled 1228 mother–child dyads in South China. GDM was diagnosed at 24–28 weeks of gestation. Neonatal circulating amino acids and lipid metabolites (carnitines) were measured from newborn heel blood 3–7 days postpartum. Offspring neurodevelopment was assessed at age 1 year using the Children Neuropsychological and Behavioral Examination Scale. Neurodevelopmental disorders were defined as developmental delay in any domain of the scale. Results: Twenty-one metabolites associated with GDM were identified, consisting of seven amino acids and fourteen carnitines. Among these metabolites, five (glycine, myristicylcarnitine, palmitoylcarnitine, octadecadienoylcarnitine, and 3-hydroxypalmitylcarnitine) mediated the negative association of GDM with offspring neurodevelopment at 1 year (mediation proportions: 3.91–10.66%). Furthermore, six metabolites (glycine, methionine, malonylcarnitine, isovalerylcarnitine, palmitoylcarnitine, and octadecadienoylcarnitine) significantly increased the predictive performance for offspring neurodevelopmental disorders at 1 year over five traditional risk factors including GDM, parity, infant sex, birth weight, and feeding patterns (area under curve: 0.762 vs. 0.718, p = 0.012). Conclusions: GDM was associated with a variety of amino acid and lipid metabolic alterations in neonatal circulation, among which certain metabolites mediated the association of GDM with adverse neurodevelopmental outcomes in offspring. Moreover, some neonatal circulating metabolites may serve as potential biomarkers that improved the prediction of offspring neurodevelopmental disorders over GDM and other traditional risk factors.

21 November 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
XWXiaotong Wang
Xiaotong Wang
JJJiajia Jing
Jiajia Jing
SHSaijun Huang
Saijun Huang
XHXiaoying He
Xiaoying He
PGPingming Gao
Pingming Gao
YZYanna Zhu
Yanna Zhu
Anemia is associated with neurodevelopmental delays and brain injury in infants and toddlers, but whether early anemia has a similar effect in neonatal preterm infants is largely unknown. Thus, this study aimed to determine the relationship of early anemia with neurodevelopment and brain injury in very-low-birth-weight (VLBW) preterm infants within the neonatal period. A prospective cohort study including 110 VLBW preterm infants was conducted in Southern China from 2016 to 2018. All participants were followed from birth to 1 month corrected age. Early anemia is defined as hemoglobin of ≤145 g/L within the first week after birth. The non-anemic group (control group, N = 55) was 1:1 matched with the early anemia group (N = 55) according to birth weight and gestational age. Neurodevelopment at 1 month corrected age and brain injury within 1 month corrected age were measured by neonatal behavioral neurological assessments (NBNA) and cranial ultrasound, respectively. Compared to the control group, the early anemia group had a lower score in behavioral ability in the NBNA test [11 (10–12) vs. 10 (9.5–11), p = 0.033]. Early anemia was negatively associated with the NBNA total score (β= −0.680, 95% CI: −1.300, −0.059), especially with the behavioral ability score (β= −0.504, 95% CI: −0.941, −0.067) after adjusting for the confounders. However, no association between early anemia and brain injury was observed. In conclusion, in VLBW preterm infants, early anemia is negatively correlated with neurodevelopment, especially with behavioral ability.